Our Products and Technologies
IMB’s Lead Product Candidate, Occlusin 500 Artificial Embolization Device (OCL 500), is a “first in class” biodegradable embolic agent for the treatment of malignant and non-malignant vascularised tumors. Examples of vascularised tumors include heptocellular carcinoma (HCC; liver cancer), renal cell carcinoma (RCC; kidney cancer) and uterine fibroids.
OCL 500 is a medical device cleared by the FDA for treatment of hypervascularized tumors. An embolic agent blocks the blood supply to a target tissue. In contrast to currently marketed embolic agents that are permanent implants, OCL 500 has the unique advantage of biodegradability. Permanent implants remain in the body while biodegradable OCL 500 is gradually removed from the body leading to reopening of the blocked blood vessel (recanalization). Further, OCL 500 remains localized to the site of administration. Since OCL 500 is classified as a medical device rather than a drug or biologic product, the regulatory requirements are greatly reduced, which translates into lower development costs and a quicker time to market.